PURPOSE: To assess the impact of ethnicity, age, and ocular characteristics on ranibizumab efficacy in myopic choroidal neovascularization (CNV). METHODS: In this post hoc subgroup analysis from the phase III RADIANCE study, best-corrected visual acuity (BCVA) outcomes and treatment exposure were analyzed in 105 patients treated withranibizumab 0.5 mg. Baseline categories included ethnicity, age, baseline BCVA, lesion area, CNV lesion area, refraction sphere, axial length, subretinal fluid, and location of CNV. RESULTS: At month 12, the mean change in BCVA was numerically higher in East-Asians than in Caucasians (17.0 vs. 14.1 letters). The median number of injections varied with ethnicity (East-Asians vs. Caucasians: 2 vs. 3), baseline BCVA (highest vs. lowest: 1 vs. 4), CNV lesion area and lesion area (largest vs. smallest: 5 vs. 1 and 5 vs. 2). CONCLUSIONS: East-Asians showed numerically higher BCVA gains than Caucasians. The number of injections varied across subgroups, emphasizing the need for individualized treatment.
RCT Entities:
PURPOSE: To assess the impact of ethnicity, age, and ocular characteristics on ranibizumab efficacy in myopic choroidal neovascularization (CNV). METHODS: In this post hoc subgroup analysis from the phase III RADIANCE study, best-corrected visual acuity (BCVA) outcomes and treatment exposure were analyzed in 105 patients treated with ranibizumab 0.5 mg. Baseline categories included ethnicity, age, baseline BCVA, lesion area, CNV lesion area, refraction sphere, axial length, subretinal fluid, and location of CNV. RESULTS: At month 12, the mean change in BCVA was numerically higher in East-Asians than in Caucasians (17.0 vs. 14.1 letters). The median number of injections varied with ethnicity (East-Asians vs. Caucasians: 2 vs. 3), baseline BCVA (highest vs. lowest: 1 vs. 4), CNV lesion area and lesion area (largest vs. smallest: 5 vs. 1 and 5 vs. 2). CONCLUSIONS: East-Asians showed numerically higher BCVA gains than Caucasians. The number of injections varied across subgroups, emphasizing the need for individualized treatment.
Authors: Alexandr Stepanov; Martin Pencak; Jan Nemcansky; Veronika Matuskova; Marketa Stredova; David Beran; Jan Studnicka Journal: J Ophthalmol Date: 2020-05-12 Impact factor: 1.909
Authors: David Blánquez-Martínez; Xando Díaz-Villamarín; Sonia García-Rodríguez; Alba Antúnez-Rodríguez; Ana Pozo-Agundo; Luis Javier Martínez-González; José Ignacio Muñoz-Ávila; Cristina Lucía Dávila-Fajardo Journal: Pharmaceutics Date: 2022-07-26 Impact factor: 6.525
Authors: Robin D Hamilton; Andreas Clemens; Angelo Maria Minnella; Timothy Y Y Lai; Hong Dai; Taiji Sakamoto; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Cornelia Dunger-Baldauf; Frank G Holz Journal: PLoS One Date: 2020-01-21 Impact factor: 3.240